FocalTherics (FOCL) Expected to Release Earnings on Thursday

FocalTherics (NASDAQ:FOCL) is expected to post its Q2 2026 results before the market opens on Thursday, August 27th. Analysts expect the company to post earnings of ($0.2287) per share and revenue of $22.4840 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million for the quarter. On average, analysts expect FocalTherics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

FocalTherics Stock Up 5.0%

FOCL opened at $4.39 on Wednesday. FocalTherics has a twelve month low of $1.37 and a twelve month high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.38 and a current ratio of 1.60. The stock’s 50-day moving average is $5.33. The firm has a market cap of $164.76 million, a P/E ratio of -4.26 and a beta of -0.04.

Analyst Ratings Changes

Several equities research analysts have commented on FOCL shares. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price target on shares of FocalTherics in a research note on Friday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday. Finally, Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.75.

Insider Activity

In other FocalTherics news, Director David R. Horn acquired 10,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 10,000 shares in the company, valued at approximately $47,500. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lance Willsey bought 50,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the completion of the purchase, the director directly owned 1,291,780 shares in the company, valued at approximately $6,135,955. This represents a 4.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 116,000 shares of company stock valued at $551,000 in the last ninety days. 10.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On FocalTherics

A hedge fund recently bought a new stake in FocalTherics stock. Kovack Advisors Inc. purchased a new position in shares of FocalTherics (NASDAQ:FOCL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 16,000 shares of the company’s stock, valued at approximately $53,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.